Abstract
P53 and mdm2 are linked to each other through a negative feedback loop. P53 transactivates mdm2, but mdm2, in turn, is a major opponent of p53. Mdm2 promotes p53 degradation through a ubiquitin-dependent pathway on 26S proteasomes and is thought to be largely responsible for the very low levels of p53 protein in unstressed cells. The rationale for targeting the p53-mdm2 interaction therapeutically lies in the ability to activate p53 in all those tumors that retain wild type p53. (C) 2000 Harcourt Publishers Ltd.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 217-221 |
| Number of pages | 5 |
| Journal | Drug Resistance Updates |
| Volume | 3 |
| Issue number | 4 |
| DOIs | |
| State | Published - Jan 1 2000 |
| Externally published | Yes |
ASJC Scopus subject areas
- Oncology
- Pharmacology
- Cancer Research
- Infectious Diseases
- Pharmacology (medical)
Fingerprint Dive into the research topics of 'Disrupting the p53-mdm2 interaction as a potential therapeutic modality'. Together they form a unique fingerprint.
Cite this
Moll, U. M., & Zaika, A. (2000). Disrupting the p53-mdm2 interaction as a potential therapeutic modality. Drug Resistance Updates, 3(4), 217-221. https://doi.org/10.1054/drup.2000.0160